Literature DB >> 23584293

New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma.

Naoki Yanagawa1, Satoshi Shiono, Masami Abiko, Shin-ya Ogata, Toru Sato, Gen Tamura.   

Abstract

INTRODUCTION: The purpose of this study is to analyze and validate the prognostic impact of the new lung adenocarcinoma (ADC) classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society and invasive tumor size in stage I lung ADC of Japanese patients.
METHODS: We reclassified 191 stage I ADCs according to the new classification. The percentage of each histological subtype and the predominant type were determined. In addition, both total tumor size and invasive tumor size were examined. The relationship between these results and clinicopathological backgrounds was investigated statistically.
RESULTS: The 5-year disease-free survival (DFS) of adenocarcinoma in situ and minimally invasive adenocarcinoma was 100%; lipidic-predominant ADCs, 94.9%; papillary-predominant ADCs, 85.4%; acinar-predominant ADCs, 89.7%; and solid-predominant ADCs, 54%. The predominant growth pattern was significantly correlated with DFS (p < 0.001, overall). With regard to tumor size, total tumor size was not correlated with DFS (p = 0.475, overall), however, invasive tumor size was significantly correlated with DFS (≤ 0.5 cm/ > 0.5 cm, ≤ 1 cm/ >1 cm, ≤ 2 cm/>2 cm, ≤ 3 cm/ >3 cm, 100%/91.5%/85.9%/80.8%/66.7%% in 5-year DFS) (p = 0.006, overall). A multivariate analysis showed solid-predominant and invasive tumor size were independent predictors of increased risk of recurrence (solid versus nonsolid: hazard ratio = 4.08, 95% confidence interval:1.59-10.5, p = 0.003; invasive tumor size: hazard ratio = 2.04, 95% confidence interval:1.14-3.63, p = 0.016).
CONCLUSION: : The new International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society ADC classification and invasive tumor size are very useful predictors of recurrence of stage I ADCs in Japanese patients.

Entities:  

Mesh:

Year:  2013        PMID: 23584293     DOI: 10.1097/JTO.0b013e318287c3eb

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  61 in total

Review 1.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

2.  Clinicopathologic correlates of postoperative N1 or N2 nodal upstaging in non-small cell lung cancer.

Authors:  Youngkyu Moon; Kyo Young Lee; Kyung Soo Kim; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  Histological subtypes of solitary pulmonary nodules of adenocarcinoma and their clinical relevance.

Authors:  Hui-Di Hu; Ming-Yue Wan; Chun-Hua Xu; Ping Zhan; Jue Zou; Qian-Qian Zhang; Yuan-Qing Zhang
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 4.  A proposal of postoperative follow-up pathways for lung cancer.

Authors:  Shigeki Sawada; Satoshi Shiono; Yoshinori Yamashita; Tsutomu Tagawa; Hiroyuki Ito; Toshihiko Sato; Hiroaki Harada; Motohiro Yamashita
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-12-18

Review 5.  Validation of the new IASLC/ATS/ERS lung adenocarcinoma classification: a surgeon's perspective.

Authors:  Raffaele Rocco; David R Jones; Alessandro Morabito; Renato Franco; Elvira La Mantia; Gaetano Rocco
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

6.  Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma.

Authors:  Ye Xu; Chen Zhu; Wenliang Qian; Min Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-13       Impact factor: 4.553

7.  Verification of T descriptor with consolidation size for sub-centimeter non-small cell lung cancer.

Authors:  Masaki Goto; Koji Kawaguchi; Takayuki Fukui; Shota Nakamura; Shuhei Hakiri; Naoki Ozeki; Shunsuke Mori; Kumiko Hashimoto; Toshinari Ito; Kohei Yokoi
Journal:  Surg Today       Date:  2019-05-22       Impact factor: 2.549

8.  Differential expression of inflammasomes in lung cancer cell lines and tissues.

Authors:  Hui Kong; Yanli Wang; Xiaoning Zeng; Zailiang Wang; Hong Wang; Weiping Xie
Journal:  Tumour Biol       Date:  2015-04-25

9.  Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Authors:  Ming-Sound Tsao; Sophie Marguet; Gwénaël Le Teuff; Sylvie Lantuejoul; Frances A Shepherd; Lesley Seymour; Robert Kratzke; Stephen L Graziano; Helmut H Popper; Rafael Rosell; Jean-Yves Douillard; Thierry Le-Chevalier; Jean-Pierre Pignon; Jean-Charles Soria; Elisabeth M Brambilla
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

10.  Analysis of the clinicopathologic characteristics and prognostic of stage I invasive mucinous adenocarcinoma.

Authors:  Jizhuang Luo; Rui Wang; Baohui Han; Jie Zhang; Heng Zhao; Wentao Fang; Qingquan Luo; Jun Yang; Yunhai Yang; Lei Zhu; Tianxiang Chen; Xinghua Cheng; Qingyuan Huang; Yiyang Wang; Jiajie Zheng; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-24       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.